A detailed history of Rhenman & Partners Asset Management Ab transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Rhenman & Partners Asset Management Ab holds 71,750 shares of NBIX stock, worth $9.01 Million. This represents 0.69% of its overall portfolio holdings.

Number of Shares
71,750
Previous 75,555 5.04%
Holding current value
$9.01 Million
Previous $10.4 Million 20.58%
% of portfolio
0.69%
Previous 1.03%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$114.58 - $153.15 $435,976 - $582,735
-3,805 Reduced 5.04%
71,750 $8.26 Million
Q2 2024

Aug 13, 2024

BUY
$130.86 - $143.19 $2.17 Million - $2.37 Million
16,555 Added 28.06%
75,555 $10.4 Million
Q1 2024

May 14, 2024

SELL
$130.4 - $143.74 $391,200 - $431,220
-3,000 Reduced 4.84%
59,000 $8.14 Million
Q4 2023

Feb 13, 2024

BUY
$106.07 - $132.76 $788,524 - $986,937
7,434 Added 13.62%
62,000 $8.17 Million
Q3 2023

Nov 13, 2023

BUY
$94.02 - $117.1 $1.37 Million - $1.71 Million
14,566 Added 36.42%
54,566 $6.14 Million
Q2 2023

Aug 11, 2023

SELL
$89.53 - $104.87 $2.69 Million - $3.15 Million
-30,000 Reduced 42.86%
40,000 $3.77 Million
Q1 2023

May 11, 2023

SELL
$94.11 - $123.02 $1.41 Million - $1.85 Million
-15,000 Reduced 17.65%
70,000 $7.09 Million
Q4 2022

Feb 13, 2023

BUY
$106.72 - $127.06 $213,440 - $254,120
2,000 Added 2.41%
85,000 $10.2 Million
Q3 2022

Nov 14, 2022

SELL
$92.03 - $107.81 $1.1 Million - $1.29 Million
-12,000 Reduced 12.63%
83,000 $9.56 Million
Q2 2022

Aug 12, 2022

SELL
$75.79 - $100.07 $757,900 - $1 Million
-10,000 Reduced 9.52%
95,000 $9.26 Million
Q1 2022

May 13, 2022

SELL
$72.45 - $94.81 $3.34 Million - $4.37 Million
-46,100 Reduced 30.51%
105,000 $9.84 Million
Q4 2021

Feb 11, 2022

BUY
$79.65 - $106.22 $4.47 Million - $5.96 Million
56,100 Added 59.05%
151,100 $12.8 Million
Q3 2021

Nov 12, 2021

SELL
$86.18 - $99.03 $861,800 - $990,300
-10,000 Reduced 9.52%
95,000 $9.11 Million
Q2 2021

Aug 13, 2021

SELL
$89.43 - $102.27 $4.47 Million - $5.11 Million
-50,000 Reduced 32.26%
105,000 $10.2 Million
Q1 2021

May 14, 2021

BUY
$87.57 - $119.4 $437,849 - $597,000
5,000 Added 3.33%
155,000 $15.1 Million
Q4 2020

Jan 19, 2021

BUY
$86.91 - $108.33 $6.52 Million - $8.12 Million
75,000 Added 100.0%
150,000 $14.4 Million
Q2 2020

Jul 16, 2020

SELL
$85.09 - $130.36 $4.68 Million - $7.17 Million
-55,000 Reduced 42.31%
75,000 $9.15 Million
Q1 2020

Apr 16, 2020

BUY
$75.11 - $113.76 $751,100 - $1.14 Million
10,000 Added 8.33%
130,000 $11.3 Million
Q4 2019

Jan 17, 2020

SELL
$86.8 - $118.57 $2.57 Million - $3.51 Million
-29,600 Reduced 19.79%
120,000 $12.9 Million
Q3 2019

Oct 16, 2019

SELL
$83.82 - $101.5 $2.55 Million - $3.09 Million
-30,400 Reduced 16.89%
149,600 $13.5 Million
Q2 2019

Jul 22, 2019

BUY
$72.24 - $91.27 $210,146 - $265,504
2,909 Added 1.64%
180,000 $15.2 Million
Q1 2019

Apr 11, 2019

SELL
$69.31 - $91.53 $1.66 Million - $2.2 Million
-24,000 Reduced 11.93%
177,091 $15.6 Million
Q4 2018

Feb 05, 2019

BUY
$68.32 - $124.36 $8.16 Million - $14.9 Million
119,414 Added 146.2%
201,091 $14.4 Million
Q3 2018

Oct 03, 2018

SELL
$98.88 - $125.85 $2.84 Million - $3.61 Million
-28,700 Reduced 26.0%
81,677 $10 Million
Q2 2018

Jul 20, 2018

BUY
$75.3 - $105.99 $28,388 - $39,958
377 Added 0.34%
110,377 $10.8 Million
Q1 2018

Apr 11, 2018

SELL
$75.88 - $92.43 $604,687 - $736,574
-7,969 Reduced 6.76%
110,000 $9.12 Million
Q4 2017

Jan 19, 2018

BUY
$58.53 - $77.59 $173,775 - $230,364
2,969 Added 2.58%
117,969 $9.15 Million
Q3 2017

Oct 13, 2017

BUY
$47.97 - $61.28 $5.52 Million - $7.05 Million
115,000
115,000 $7.05 Million

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $12B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Rhenman & Partners Asset Management Ab Portfolio

Follow Rhenman & Partners Asset Management Ab and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhenman & Partners Asset Management Ab, based on Form 13F filings with the SEC.

News

Stay updated on Rhenman & Partners Asset Management Ab with notifications on news.